Rationale: Human rhinovirus (HRV) is most prominently associated with asthma exacerbations in humans. The U-BIOPRED project of the Innovative Medicine Initiative (IMI) aims to define biomarkers of asthma exacerbations for distinct phenotypes to enable a better prediction of therapeutic efficacy.
Conclusions:
The established model represented partly signs of exacerbating asthma pathology.
While classical airway inflammation parameters were not affected, clinical signs of virus induced exacerbation were obvious by the health condition of the affected animals not clearly translated to valid read out parameters. As steroid insensitivity of asthma patients is an important problem in treatment of the disease, steroid efficacy will be investigated next in this model to establish a complete model for preclinical drug testing. 
